NeoGenomics (NASDAQ:NEO) Rating Increased to Sell at StockNews.com

NeoGenomics (NASDAQ:NEOGet Rating) was upgraded by StockNews.com to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts also recently weighed in on NEO. Benchmark dropped their target price on shares of NeoGenomics from $26.00 to $16.00 in a research note on Tuesday, March 29th. Bank of America downgraded shares of NeoGenomics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $25.00 to $18.00 in a research note on Tuesday, March 29th. Raymond James dropped their price target on shares of NeoGenomics from $24.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday, April 18th. BTIG Research dropped their price target on shares of NeoGenomics from $35.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, March 29th. Finally, SVB Leerink dropped their price target on shares of NeoGenomics from $45.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, March 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $24.64.

Shares of NeoGenomics stock opened at $9.45 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 7.54 and a current ratio of 7.81. The firm’s 50-day simple moving average is $15.22 and its 200-day simple moving average is $26.73. NeoGenomics has a twelve month low of $9.34 and a twelve month high of $54.74. The firm has a market cap of $1.17 billion, a P/E ratio of -85.90 and a beta of 0.74.

NeoGenomics (NASDAQ:NEOGet Rating) last issued its earnings results on Wednesday, April 27th. The medical research company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. NeoGenomics had a negative net margin of 1.72% and a negative return on equity of 4.17%. The business had revenue of $117.17 million for the quarter, compared to analyst estimates of $116.44 million. During the same period in the previous year, the business earned ($0.06) EPS. The firm’s revenue was up 1.4% on a year-over-year basis. On average, equities analysts forecast that NeoGenomics will post -0.87 earnings per share for the current fiscal year.

In other news, CFO William Bonello sold 3,209 shares of the stock in a transaction dated Monday, March 7th. The shares were sold at an average price of $18.29, for a total value of $58,692.61. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. Arizona State Retirement System raised its position in shares of NeoGenomics by 1.1% in the 3rd quarter. Arizona State Retirement System now owns 30,516 shares of the medical research company’s stock valued at $1,471,000 after buying an additional 318 shares in the last quarter. Mariner LLC raised its position in shares of NeoGenomics by 0.7% in the 3rd quarter. Mariner LLC now owns 52,165 shares of the medical research company’s stock valued at $2,516,000 after buying an additional 351 shares in the last quarter. Profund Advisors LLC grew its holdings in shares of NeoGenomics by 3.8% during the 3rd quarter. Profund Advisors LLC now owns 13,205 shares of the medical research company’s stock valued at $637,000 after purchasing an additional 485 shares during the last quarter. Oak Family Advisors LLC grew its holdings in shares of NeoGenomics by 1.0% during the 4th quarter. Oak Family Advisors LLC now owns 58,120 shares of the medical research company’s stock valued at $1,983,000 after purchasing an additional 555 shares during the last quarter. Finally, Valmark Advisers Inc. grew its holdings in shares of NeoGenomics by 6.6% during the 4th quarter. Valmark Advisers Inc. now owns 9,202 shares of the medical research company’s stock valued at $314,000 after purchasing an additional 570 shares during the last quarter. Institutional investors and hedge funds own 97.04% of the company’s stock.

About NeoGenomics (Get Rating)

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.

Featured Articles

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.